Publications by authors named "N Heerema"
Limited prognostic factors have been associated with overall survival (OS) post-relapse in childhood Acute Lymphoblastic Leukemia (ALL). Patients enrolled on 12 Children's Oncology Group frontline ALL trials (1996-2014) were analyzed to assess for additional prognostic factors associated with OS post-relapse. Among 16,115 patients, 2053 (12.
View Article and Find Full Text PDFArticle Synopsis
- Despite high cure rates for childhood acute lymphoblastic leukemia (ALL), it remains a major cause of cancer-related deaths in children, especially among those initially classified as standard-risk (SR).
- Researchers analyzed genomic data from over 1,300 children with ALL to identify factors influencing relapse, focusing on comparing patients who relapsed against those who stayed in remission for five years.
- Findings indicated that specific genomic subtypes and chromosomal alterations significantly affect relapse risk, highlighting the need for detailed genetic analysis to improve risk assessment and treatment strategies in childhood ALL.
Article Synopsis
- The 2022 European LeukemiaNet (ELN) classification predicts outcomes for younger acute myeloid leukemia (AML) patients but was tested for those aged 60 and older receiving lower-intensity treatment (LIT), involving 595 patients with varying risk levels.
- Results showed that while ELN risk is predictive of overall survival, it fails to distinguish between favorable and intermediate risks, prompting further exploration into adverse-risk patients' molecular abnormalities.
- A new "Beat-AML" risk classification was developed, combining favorable and intermediate risks and integrating mutation scoring, leading to better survival predictions for older AML patients and aiding treatment decisions with clear risk group delineations.
Infants less than 1 year old diagnosed with KMT2A-rearranged (KMT2A-r) acute lymphoblastic leukemia (ALL) are at high risk of failure to achieve remission, relapse, and death due to leukemia, despite intensive therapies. Infant KMT2A-r ALL blasts are characterized by DNA hypermethylation. Epigenetic priming with DNA methyltransferase inhibitors increases the cytotoxicity of chemotherapy in preclinical studies.
View Article and Find Full Text PDF